Welcome to our dedicated page for Renovaro news (Ticker: RENB), a resource for investors and traders seeking the latest updates and insights on Renovaro stock.
Lunai Bioworks Inc. (NASDAQ: RENB, later LNAI) generates a steady flow of news at the intersection of biomedical research, artificial intelligence, and biodefense. Company press releases and regulatory filings highlight developments in AI-powered drug discovery, immuno-oncology, precision neurology, and national security-related countermeasure initiatives. This news page aggregates those updates for investors and observers who want a single view of the company’s publicly reported activities.
Recent communications describe Lunai Bioworks as an AI-powered drug discovery and biodefense company with a strong focus on generative biology and dual-use risk management. Through its wholly owned subsidiary BioSymetrics, the company reports progress in biomarker discovery programs for Parkinson’s disease and in AI-driven platforms for Alcohol Use Disorder drug discovery, supported by a Small Business Technology Transfer grant from the National Institutes of Health. News items also cover peer-reviewed preclinical data on a dendritic cell therapy platform for pancreatic and other solid tumors, reflecting the company’s roots in oncology and immunotherapy.
Lunai Bioworks’ news flow also includes technology and policy-oriented announcements. The company has announced a transformer-based platform that embeds biological risk intelligence into large language model pipelines to screen for potentially toxic compounds and address concerns about misuse of generative AI. Other releases describe collaborations aimed at applying its AI-enabled biomedical platforms to chemical and biological weapons countermeasures, as well as commentary on its role in broader discussions about AI and biodefense risk.
Corporate and capital markets updates appear alongside scientific and technical news. These include the corporate name change from Renovaro Inc. to Lunai Bioworks Inc., the implementation of a 1-for-10 reverse stock split, and Nasdaq notifications related to listing standards such as minimum bid price, annual meeting requirements, and market value of listed securities. By reviewing this news stream, readers can follow how Lunai Bioworks presents its strategy, technology platforms, collaborations, and regulatory milestones over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.